March 19 (Reuters) - AstraZeneca said on Tuesday it has agreed to buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash.
The drugmaker will pay $21 per Fusion share plus a non-transferable contingent value right of $3 per share. (Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio D'Souza)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Nancy Pelosi's husband Paul Pelosi uses an investing strategy that lowers upfront costs.
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.
This leading semiconductor company could turbocharge your returns.
Here's what could happen next to Alphabet shares.
In addition to economic and earnings news, inflation and geopolitical worries will have roles to play.
Nvidia and several other leaders flashed buy signals as the market roared. Investors should take advantage, but it's a jungle out there.
The tobacco giant will soon be allowed to sell a proven product in a proven market.
The $50 million purchase could turn into Nvidia's biggest investment.
The market's pricing in all of the bad and none of the good.